Aripiprazole in the pharmacotherapy of Gilles de la Tourette syndrome in adult patients

References

• Albin RL, Mink JW. Recent advances in Tourette syndrome research. Trends Neurosci 2006; 29: 175–182
   PubMed Web of Science ®Google Scholar
• Bruun RD. The natural history of Tourette's syndrome. Tourette's syndrome and tic disorders. Clinical understanding and treatment, DJ Cohen, RD Bruun, JF Leckman. Wiley, New York 1988; 21–39
   Google Scholar
• Bubl E, Perlov E, Tebartz Van Elst L. Aripiprazole in patients with Tourette syndrome. World J Biol Psychiatry 2006; 7: 123–125
   PubMed Web of Science ®Google Scholar
• Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381–389
   PubMed Web of Science ®Google Scholar
• Constant EL, Borras L, Seghers A. Aripiprazole is effective in the treatment of Tourette's disorder. Int J Neuropsychopharmacol 2006; 9: 773–774
   PubMed Web of Science ®Google Scholar
• Davies L, Stern JS, Agrawal N, Robertson MM. A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 2006; 21: 447–453
   PubMed Web of Science ®Google Scholar
• Dehning S, Riedel M, Muller N. Aripiprazole in a patient vulnerable to side effects. Am J Psychiatry 2005; 162: 625
   PubMedGoogle Scholar
• Duane DD. Aripiprazole in childhood and adolescence for Tourette syndrome. J Child Neurol 2006; 21: 358
   PubMed Web of Science ®Google Scholar
• Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45: 71–76
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Siamouli M, Kantartzis S, Panagiotidis P, Iacovides A, Kaprinis GS. Acute dystonia with low-dosage aripiprazole in Tourette's disorder. Ann Pharmacother 2006; 40: 775–777
   PubMed Web of Science ®Google Scholar
• Gründer G, Landvogt C, Vernaleken I, et al. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 2006; 31: 1027–1035
   PubMed Web of Science ®Google Scholar
• Hounie A, De Mathis A, Sampaio AS, Mercadante MT. [Aripiprazole and Tourette syndrome]. Rev Bras Psiquiatr 2004; 26: 213
   PubMedGoogle Scholar
• Janouschek H, Vernaleken I, Boy C, et al. Das temporale und extrastriatale D2/D3-Rezeptor-Bindungsprofil von Aripiprazol bei Patienten mit schizophrener oder schizoaffektiver Psychose. Der Nervenarzt 2006; 77: S160
   Google Scholar
• Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441: 137–140
   PubMed Web of Science ®Google Scholar
• Kastrup A, Schlotter W, Plewnia C, Bartels M. Treatment of tics in tourette syndrome with aripiprazole. J Clin Psychopharmacol 2005; 25: 94–96
   PubMed Web of Science ®Google Scholar
• Kessler RM, Ansari MS, Riccardi P, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006; 31: 1991–2001
   PubMed Web of Science ®Google Scholar
• Kim BN, Lee CB, Hwang JW, Shin MS, Cho SC. Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea. J Child Adolesc Psychopharmacol 2005; 15: 318–324
   PubMedGoogle Scholar
• Leckman JF, King RA, Cohen DJ. Tics and tic disorders. Tics, obsessions, compulsions: Developmental psychopathology and clinical care, JF Leckman, DJ Cohen. Wiley & Sons, New York 1999; 23–42
   Google Scholar
• Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989; 28: 566–573
   PubMed Web of Science ®Google Scholar
• Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004; 161: 818–825
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Petersen RC. Treatment of Gilles de la Tourette's syndrome: eight-year, practice-based experience in a predominantly adult population. Neurology 1987; 37: 1828–1833
   PubMedGoogle Scholar
• Miranda CM, Castiglioni TC. [Aripiprazole for the treatment of Tourette syndrome. Experience in 10 patients.]. Rev Med Chil 2007; 135: 773–776
   PubMedGoogle Scholar
• Müller N. Tics. Bewegungsstörungen bei psychischen Erkrankungen Berlin, T Jahn. Springer, Heidelberg, New York 2004; 215–231
   Google Scholar
• Murphy TK, Bengtson MA, Soto O, et al. Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol 2005; 8: 489–490
   PubMed Web of Science ®Google Scholar
• Padala PR, Qadri SF, Madaan V. Aripiprazole for the treatment of Tourette's disorder. Prim Care Companion J Clin Psychiatry 2005; 7: 296–299
   PubMedGoogle Scholar
• Rickards H, Robertson M. A controlled study of psychopathology and associated symptoms in Tourette syndrome. World J Biol Psychiatry 2003; 4: 64–68
   PubMed Web of Science ®Google Scholar
• Rothenberger, A, Banaschewski, T. Tic-Störungen (F. 95). In:. Arbeitsgemeinschaft Medizinischer Fachgesellschaften (AWMF). Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. 2003. Cologne: Deutscher Ärzte Verlag. 311–317.
   Google Scholar
• Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000; 39: 292–299
   PubMed Web of Science ®Google Scholar
• Seignot JN. [A case of tic of Gilles de la Tourette cured by R 1625.]. Ann Med Psychol 1961; 119: 578–579
   PubMedGoogle Scholar
• Singer HS. Neurobiology of Tourette syndrome. Neurol Clin North Am 1997; 15: 357–375
   PubMed Web of Science ®Google Scholar
• Tanner CM, Goldman SM. Epidemiology of Tourette syndrome. Neurol Clin 1997; 15: 395–402
   PubMedGoogle Scholar
• Vernaleken I, Siessmeier T, Buchholz HG, et al. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol 2004; 7: 421–430
   PubMedGoogle Scholar
• Yoo HK, Kim JY, Kim CY. A pilot study of aripiprazole in children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol 2006; 16: 505–506
   PubMed Web of Science ®Google Scholar
• Yoo HK, Choi SH, Park S, Wang HR, Hong JP, Kim CY. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry 2007; 68: 1088–1093
   PubMed Web of Science ®Google Scholar